Sclerotherapy in Vascular Malformations

  • Juan Carlos Cabrera
  • Dirk A. Loose


Sclerotherapy is performed mainly in venous and lymphatic malformations using different substances. Sclerosis in arteriovenous (AV) forms is contraindicated because an erroneous intra-arterial injection may produce extensive necrosis. Classical sclerosis is mainly performed in venous dysplasias with polidocanol, sodium tetradecyl sulphate and ethanol, among others, while in lymphatic malformations, OK-432 is preferred. Sclerotherapy with the microfoam technique significantly improves results.


Vascular Malformation Venous Malformation Lymphatic Malformation Ethanolamine Oleate Sodium Morrhuate 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Belov S, Loose DA, Weber J (eds) (1989) Vascular malformations. Periodica Angiologica, vol 16. Einhorn Presse Verlag, Reinbek, vol 16, pp 25–27Google Scholar
  2. 2.
    Mulliken JB, Young AE (1988) Vascular birthmarks: hemangiomas and malformations. WB Saunders, PhiladelphiaGoogle Scholar
  3. 3.
    Loose DA (2001) Modern tactics and techniques in the treatment of angiodysplasias of the foot. Chir del Piede 25:1–17Google Scholar
  4. 4.
    Lee BB, Mattassi R, Loose DA et al (2005) Consensus on controversial issues in contemporary diagnosis and management of congenital vascular malformation: Seoul communication. Int J Angiol 13:182–192CrossRefGoogle Scholar
  5. 5.
    Loose DA (2007) Surgical management of venous malformations. Phlebology 22:276–282CrossRefPubMedGoogle Scholar
  6. 6.
    Yakes WF, Luethke JM, Parker SH et al (1990) Ethanol embolization of vascular malformations. Radiographics 10:787–796PubMedGoogle Scholar
  7. 7.
    De Lorimier AA (1995) Sclerotherapy for venous malformations. J Pediatr Surg 30:188–194CrossRefPubMedGoogle Scholar
  8. 8.
    Claesson G, Kuyelenstierna R (2002) OK-432 therapy for lymphatic malformation in 32 patients (28 children). Int J Pediatr Otorhinolaryngol 65:1–6CrossRefPubMedGoogle Scholar
  9. 9.
    Villavicencio JL (2001) Primum non nocere: Is it always true? The use of absolute ethanol in the management of congenital vascular malformations. J Vasc Surg 33:904–906CrossRefPubMedGoogle Scholar
  10. 10.
    Belov S (1998) Late results in the treatment of vascular malformations. Int Angiol 7:136–143CrossRefGoogle Scholar
  11. 11.
    Cabrera J, Cabrera J Jr, García-Olmedo MA (1997) Elargissement des limites de la sclerotherapie: Nouveaux produits sclerosants. Phlebologie 2:181–188Google Scholar
  12. 12.
    Cabrera J, Cabrera J Jr, García-Olmedo MA (2000) Treatment of varicose long saphenous veins with sclerosant in microfoam form: long-term outcomes. Phebology 15:19–23CrossRefGoogle Scholar
  13. 13.
    Cabrera J, Cabrera J Jr (1997) BTG International Limited Assignee. Injectable microfoam containing a sclerosing agent. US patent 5676962Google Scholar
  14. 14.
    Bikerman JJ (1973) Foams. Springer-Verlag, New YorkGoogle Scholar
  15. 15.
    Cabrera J, Cabrera J Jr, GarcÍa-Olmedo MA, Redondo P (2003) Treatment of venous malformations with sclerosant in microfoam form. Arch Dermatol 139:1409–1416CrossRefPubMedGoogle Scholar
  16. 16.
    Belov S (1990) Classification of congenital vascular defects. Int Angiol 9:141–146PubMedGoogle Scholar

Copyright information

© Springer-Verlag Italia 2009

Authors and Affiliations

  • Juan Carlos Cabrera
    • 1
  • Dirk A. Loose
    • 2
  1. 1.Clinicas “Dr. Juan Cabrera”GranadaSpain
  2. 2.Center for Circulatory Disturbances and Vascular Defects, Department for Angiology and Vascular SurgeryFacharztklinik HamburgHamburgGermany

Personalised recommendations